CPHI Milan 2026
10/2026 – 10/2026
About Company
- Legal Name: Yuxi Walvax Biotechnology Co., Ltd.
- Registered country: China
- Address: 83 South Dongfeng Road, Yuxi • Yunnan
- Number of employees: 1000 - 4999
- Established year: 2001
Description:
Founded in 2001, Walvax Biotechnology Co. Ltd. is mainly engaged in researching, developing, manufacturing and distributing safe, efficacious human vaccines. A leading publicly listed company in China, Walvax has successfully developed 9 licensed vaccines (13 presentations), including the world's 2nd approved PCV-13 vaccine, 4th approved mRNA COVID-19 vaccine, and 5th approved HPV vaccine.
Business Activities
Biopharmaceutical Products
ExporterManufacturer
ATC (Anatomical Therapeutic Chemical) Classification
Manufacturer
Sales Markets
- South Asia: Bangladesh, India
- Mainland Southeast Asia: Indonesia, Philippines
- Central Asia: Kyrgyzstan, Uzbekistan
- Northern Africa: Egypt, Morocco
- Western Africa: Nigeria, Senegal
Key Products/Services
- Biopharmaceutical Products: R&D Research and Development, Vaccines, 13-valent pneumococcal conjugate vaccine, Paediatric combination vaccines, Walrinvax meningococcal vaccine
- ATC (Anatomical Therapeutic Chemical) Classification: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Our Products & Services
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Proofs
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Leave your rating & comment